Threefold cost in high-risk heart patients – a SPESiOR study
The link between the risk of myocardial infarction recurrence and the costs of health and social services has been demonstrated in a study conducted in
Creating Insights
The link between the risk of myocardial infarction recurrence and the costs of health and social services has been demonstrated in a study conducted in
The value of one drug trial for healthcare is up to EUR 10 million According to a study we at ESiOR carried out together with
Chairing education related to artificial intelligence (AI) for real-world evidence (RWE) at AI x Pharma x Health 2024: “Explore the potential of artificial intelligence in
Multiple new ESiOR innovations are presented during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR US) main congress at Atlanta in the Unites States
The GenomiTerveys project, led by the Helsinki Biobank, has received the first-ever Biobank Research of the Year award from the Finnish Biobank Cooperative – FINBB.
In cooperation with Business Finland and the Fingenious Ecosystem, ESiOR will be part of the trade mission to Denmark on 27-28 November. After this, we
ISPOR is the biggest conference of Health Economics and Pharmacoeconomics. This year the European conference will take place in Copenhagen, Denmark on 12-15 November. The
Are you ready to unlock the future of business, leadership, and innovation? Join us at the Nordic Business Forum 2023, where the world’s top business
The Brain Research Unit 2.0 (Aivotutkimusyksikkö 2.0, ATY 2.0) is a collaborative effort between the University of Eastern Finland, the Northern Savo wellbeing services county,
Erkki Soini, CEO of ESiOR and Chairman of the Board at Kuopio Health, will present at this year’s Kuopio Health Insights. The event, which will
ESiOR will participate in this year’s ATK days (ATK-päivät) in Turku, 22-24. May. ATK days have been arranged since 1975 and are a must-attend event